FluMist booms on CDC backing

• Article
• Comments ()
• Click-2-Listen
• Videos

By

Several Washington-area clinics are limiting their flu vaccination programs because of nationwide shortages and are encouraging people to take alternatives to shots.

Many local county health officials are urging eligible people to use FluMist, a nasal-spray vaccine manufactured by Gaithersburg biotechnology company MedImmune.

The shortage of traditional flu shots and an endorsement by the Centers for Disease Control and Prevention (CDC) that FluMist is effective in fighting the H3N2-Fujian flu strain are expected to boost sales of the nasal spray.

At pharmacies in 33 Giant Food stores in Virginia, FluMist sales tripled last week over the previous week, a company spokesman said.

FluMist spokeswoman Jamie Lacey said it was too soon to say how much sales would be affected due to the traditional-vaccine shortage. MedImmune had sold 400,000 doses as of Nov. 18. The company produced 4 million doses for the flu season.

FluMist, which was intended to be a non-needle alternative for children, is limited to healthy individuals between ages 5 and 50. The Food and Drug Administration excluded toddlers and seniors, the two groups at the greatest risk of the flu, because of health concerns.

Last month, MedImmune downgraded its financial outlook for 2003 based mainly on sagging FluMist sales. The company earlier predicted sales of between $120 million and $140 million for the drug, but lowered the forecast to between $55 million and $85 million.

The flu season, which generally runs from November until March, has produced a harsher than normal strain that has sent hundreds of local residents to doctors' offices and walk-in clinics during the past week.

Fairfax County officials said their supply of 300,000 flu shots would run out by today, with two of its five district offices depleted of supplies by Friday.